P00749 (UROK_HUMAN) Homo sapiens (Human)
Urokinase-type plasminogen activator UniProtKBInterProSTRINGInteractive Modelling
431 aa; Sequence (Fasta) ; (Isoform 2)
Available Structures
155 Experimental Structures
Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
---|---|---|---|---|---|---|
Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine P… |
Heteromer | 100 | 2×CIT; 1×655; | |||
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU… |
Heteromer | 100 | 2×CIT; 1×130; | |||
Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala1… |
Heteromer | 100 | 1×ESI; 3×CIT; | |||
Low molecular weigth human Urokinase type Plasminogen activator 2-[6-(3'-Aminomethyl-biphenyl-3-ylo… |
Heteromer | 100 | 1×438; | |||
Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inh… |
Heteromer | 99.19 | 2×SO4; 2×PEG; 3×EDO; 1×1PE; 1×ZBR; | |||
Crystal Structure of a Michaelis Complex between Plasminogen Activator Inhibitor-1 and Urokinase-ty… |
Heteromer P05121; | 98.78 | 2×SO4; | |||
Crystal structure of uPA in complex with a camelid-derived antibody fragment |
Heteromer | 99.19 | 5×GOL; 2×SO4; 3×TWN; 1×MES; | |||
Human urokinase-type Plasminogen Activator (uPA) in complex with a bicyclic peptide inhibitor (UK18… |
Heteromer | 99.18 | 4×SO4; 2×CL; 1×P6G; 1×ZBR; | |||
Human urokinase-type Plasminogen Activator (uPA) in complex with a bicyclic peptide inhibitor (UK18… |
Heteromer | 99.18 | 4×SO4; 1×CL; 1×P6G; 1×ZBR; | |||
The crystal structure of uPA in complex with the Fab fragment of mAb-112 |
Heteromer | 99.09 | 1×SO4; | |||
Structure of urokinase receptor, urokinase and vitronectin complex |
Heteromer P04004; Q03405; | 99.2 | 1×NAG; 2×NAG; | |||
Structure of anti-uPAR Fab ATN-658 in complex with uPAR |
Heteromer P04004; Q03405; | 99.2 | 2×NAG; 1×MAN; 1×NAG; | |||
Structure of urokinase receptor, urokinase and vitronectin complex |
Heteromer P04004; Q03405; | 99.19 | 2×NAG; 1×NAG; | |||
Crystal structure of stabilized human uPAR mutant in complex with ATF |
Heteromer Q03405; | 99.19 | 1×NAG; 2×NAG; | |||
Structure of Human Urokinase Plasminogen Activator in Complex with Urokinase Receptor and an anti-u… |
Heteromer Q03405; Q52L64; Q924Q0; | 99.18 | 1×NAG; 1×NAG; 1×SO4; 3×ETX; 2×EDO; 1×PGE; 1×NDG; 1×PG4; | |||
Crystal structure of ATF-urokinase receptor complex |
Heteromer Q03405; | 99.18 | 1×NAG; 1×SO4; | |||
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU… | homo-2-mer | 100 | 2×CIT; 1×135; | |||
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU… | homo-2-mer | 100 | 2×CIT; 1×133; | |||
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU… | homo-2-mer | 100 | 2×CIT; 1×136; | |||
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI… | homo-2-mer | 100 | 3×FLC; 1×ESP; | |||
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI… | homo-2-mer | 100 | 3×FLC; 1×ESI; | |||
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI… | homo-2-mer | 100 | 3×FLC; 1×ESI; | |||
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU… | homo-2-mer | 100 | 2×CIT; 1×132; | |||
Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala1… | homo-2-mer | 100 | 1×CR9; 2×CIT; | |||
Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala1… | homo-2-mer | 100 | 1×696; 1×CIT; | |||
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU… | homo-2-mer | 100 | 2×CIT; 1×130; | |||
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU… | homo-2-mer | 100 | 2×CIT; 1×134; | |||
A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK … | homo-2-mer | 100 | 2×CIT; 1×BMZ; | |||
A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK … | homo-2-mer | 100 | 1×120; 2×CIT; | |||
A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK … | homo-2-mer | 100 | 1×123; 2×CIT; | |||
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI… | homo-2-mer | 100 | 3×FLC; 1×BEN; | |||
LMW U-PA Structure complexed with EGRCMK (GLU-GLY-ARG Chloromethyl Ketone) | homo-2-mer | 100 | 1×0GJ; | |||
Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANID… | monomer | 99.61 | 1×QGG; | |||
Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator | monomer | 100.0 | 1×NO3; 1×AMH; | |||
Crystal structure of complex of urokinase and a upain-1 variant(W3F) in pH7.4 condition | monomer | 99.19 | ||||
The crystal structure of uPA complex with peptide inhibitor MH027 at pH4.6 | monomer | 99.19 | 1×SO4; 1×PG4; | |||
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T… | monomer | 99.6 | 1×ACT; 1×SO4; 1×L1R; | |||
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T… | monomer | 99.6 | 1×ACT; 1×VG2; | |||
Crystal structure of uPA in complex with upain-2-3-W3A | monomer | 99.19 | 1×ALA; 1×CYS; | |||
Crystal structure of uPA in complex with 6-amidino-2-naphthol | monomer | 99.19 | 1×7R8; 1×SO4; 1×PGE; | |||
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T… | monomer | 99.6 | 1×ACT; 1×L1O; | |||
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T… | monomer | 99.6 | 1×ACT; 1×SO4; 1×505; | |||
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T… | monomer | 99.6 | 1×ACT; 1×D55; | |||
Synthesis of a Weak Basic uPA Inhibitor and Crystal Structure of Complex with uPA | monomer | 99.19 | 1×11E; 1×PG6; | |||
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T… | monomer | 99.6 | 1×ACT; 1×D56; | |||
The crystal structure of uPA complex with peptide inhibitor MH027 at pH7.4 | monomer | 99.19 | 1×SO4; | |||
The crystal structure of upain-1-W3A in complex with uPA at pH7.4 | monomer | 99.19 | 1×SO4; 1×P6G; | |||
The complex crystal Structure of Urokianse and 2-Aminobenzothiazole | monomer | 99.59 | 1×SO4; 1×ABV; | |||
The crystal structure of mupain-1-17 in complex with murinised human uPA at pH4.6 | monomer | 98.78 | 2×SO4; 2×PGE; 1×MRZ; | |||
Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inh… | monomer | 99.19 | 1×1PE; 2×EDO; 1×NH2; 1×ZBR; | |||
Crystal structure of complex of urokinase and a upain-1 variant(W3A) in pH4.6 condition | monomer | 99.19 | ||||
UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-BENZAMIDINE COMPLEX | monomer | 99.59 | 2×SO4; 1×BEN; | |||
UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN INHIBITOR COMPLEX | monomer | 99.59 | 1×SO4; 1×AGB; | |||
The crystal structure of mupain-1-16 in complex with murinised human uPA at pH7.4 | monomer | 98.78 | 1×MRZ; | |||
Urokinase type plasminogen activator | monomer | 99.59 | 1×SI1; 2×SO4; | |||
The crystal structure of mupain-1--16-IG in complex with murinised human uPA at pH7.4 | monomer | 98.78 | 1×MRZ; | |||
Urokinase Plasminogen Activator B-Chain-JT463 Complex | monomer | 99.59 | 2×SO4; 1×7IN; | |||
UROKINASE TYPE PLASMINOGEN ACTIVATOR | monomer | 99.59 | 1×SM1; 2×SO4; | |||
Urokinase type plasminogen activator | monomer | 99.59 | 1×SJ1; 2×SO4; | |||
UROKINASE TYPE PLASMINOGEN ACTIVATOR | monomer | 99.59 | 2×SO4; 1×SK1; | |||
Urokinase plasminogen activator B-chain-GPPE complex | monomer | 99.59 | 1×SO4; 1×4PG; | |||
The crystal structure of mupain-1-IG in complex with murinised human uPA at pH7.4 | monomer | 98.78 | ||||
The crystal structure of mupain-1-12 in complex with murinised human uPA at pH7.4 | monomer | 98.78 | 1×PL0; | |||
The crystal structure of mupain-1-17 in complex with murinised human uPA | monomer | 98.78 | 1×MRZ; 1×SO4; | |||
UROKINASE TYPE PLASMINOGEN ACTIVATOR | monomer | 99.59 | 2×SO4; 1×SH1; | |||
The crystal structure of mupain-1 in complex with murinised human uPA at pH7.4 | monomer | 98.78 | ||||
The crystal structure of uPA complex with peptide inhibitor MH036 at pH4.6 | monomer | 99.19 | ||||
Urokinase Plasminogen Activator B-Chain-J435 Complex | monomer | 99.59 | 2×SO4; 1×2IN; | |||
UROKINASE TYPE PLASMINOGEN ACTIVATOR | monomer | 99.59 | 1×SL1; | |||
Urokinase Plasminogen Activator B-Chain-JT464 Complex | monomer | 99.59 | 2×SO4; 1×5IN; | |||
UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEX | monomer | 99.59 | 2×SO4; 1×UKP; | |||
The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH4.6 | monomer | 99.19 | 1×PZH; 1×SO4; 2×PGE; | |||
The crystal structure of upain-1-W3A in complex with uPA at pH9.0 | monomer | 99.19 | 1×SO4; 1×P6G; | |||
The crystal structure of upain-1-W3A in complex with uPA at pH5.5 | monomer | 99.18 | 1×SO4; 2×PG4; | |||
Crystal structure of uPA in complex with upain-2-2 | monomer | 99.19 | 1×SO4; | |||
Structure of PAItrap, an uPA mutant | monomer | 97.97 | 2×SO4; 2×PGE; 2×GOL; | |||
Crystal Structure of the Urokinase | monomer | 99.19 | 1×1U2; 4×SO4; 1×ACT; 7×GOL; | |||
Crystal Structure of the Urokinase | monomer | 99.19 | 3×SO4; 1×SIN; 6×GOL; 2×ACT; 1×675; | |||
Crystal structure of uPA in complex with upain-2-2-W3A | monomer | 99.19 | ||||
uPA-HMA | monomer | 99.19 | 1×HMX; 1×SO4; | |||
Crystal Structure of the Urokinase | monomer | 99.19 | 1×239; 1×SIN; 4×SO4; 1×ACT; 8×GOL; | |||
uPA-6F-HMA | monomer | 99.19 | 1×EAU; 1×SO4; | |||
Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-y… | monomer | 98.78 | 1×EAU; 1×SO4; | |||
Crystal Structure of the Urokinase | monomer | 99.19 | 1×9UP; 4×SO4; 2×GOL; 2×ACT; | |||
The crystal structure of upain-1-W3A in complex with inactive uPA (uPA-S195A) at pH7.4 | monomer | 98.78 | ||||
Crystal Structure of the Urokinase | monomer | 99.19 | 1×4UP; 1×SO4; 1×SIN; 6×GOL; 1×15P; 5×ACT; | |||
The crystal structure of mupain-1-16-D9A in complex with murinised human uPA at pH7.4 | monomer | 98.78 | 1×MRZ; | |||
The crystal structure of human urokinase-type plasminogen activator catalytic domain | monomer | 99.19 | 2×SO4; 2×P6G; | |||
Crystal structure of uPA in complex with 4-guanidinobenzoic acid | monomer | 99.19 | 1×PGE; 1×GBS; | |||
Crystal Structure of the Urokinase | monomer | 99.19 | 3×SO4; 1×ACT; 1×1UP; | |||
The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH7.4 | monomer | 99.19 | 1×PZH; 1×SO4; | |||
Crystal Structure of the Urokinase | monomer | 99.19 | 1×UI3; 3×SO4; 4×GOL; 1×NA; 1×SIN; | |||
Crystal Structure of the Urokinase | monomer | 99.19 | 1×6UP; 3×SIN; 4×SO4; 1×NA; | |||
Crystal Structure of the Urokinase | monomer | 99.19 | 1×7UP; 1×SIN; 2×SO4; 3×GOL; 2×ACT; | |||
Crystal Structure of the Urokinase | monomer | 99.19 | 1×8UP; 1×SIN; 3×SO4; 4×GOL; 3×ACT; | |||
The complex crystal Structure of Urokianse and 5-nitro-1H-indole-2-amidine | monomer | 99.59 | 1×B25; 2×SO4; | |||
Crystal Structure of the Urokinase | monomer | 99.19 | 1×1U9; 1×SIN; 2×SO4; 2×ACT; 3×GOL; | |||
New Pharmacophore for Serine Protease Inhibition Revealed by Crystal Structure of Human Urokinase-t… | monomer | 99.17 | ||||
Crystal Structure of the Urokinase | monomer | 99.19 | 1×2UP; 2×ACT; 1×SIN; 4×SO4; | |||
Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6… | monomer | 98.78 | 1×HMX; 1×SO4; | |||
Crystal structure of uPA in complex with S2444 | monomer | 99.19 | 1×7YF; | |||
Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic … | monomer | 99.16 | 1×4AL; 1×SO4; 1×PGE; | |||
The Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Pl… | monomer | 99.16 | 1×2BS; | |||
Crystal structure of uPA in complex with quercetin | monomer | 99.19 | 1×QUE; 1×PG6; | |||
The crystal structure of uPA in complex with 4-Iodobenzylamine at pH7.4 | monomer | 99.18 | 1×ZXI; | |||
Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q) in com… | monomer | 99.13 | 2×SO4; 2×1PE; 1×PEG; | |||
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK7… | monomer | 99.18 | 2×SO4; 5×GOL; 1×ACT; 1×ZBR; | |||
Human urokinase-type plasminogen activator uPA in complex with the two-disulfide bridge peptide UK5… | monomer | 99.18 | 4×SO4; 2×NA; 3×CL; 1×P6G; 1×GOL; | |||
Substituted 2-Naphthamidine inhibitors of urokinase | monomer | 99.18 | 3×SO4; 1×675; | |||
Substituted 2-Naphthamidine Inhibitors of Urokinase | monomer | 99.18 | 3×SO4; 1×239; | |||
uPA-BB2-50F | monomer | 99.18 | 1×50I; | |||
Crystal structure of uPA in complex with 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyra… | monomer | 99.18 | 1×9XF; 1×SO4; | |||
uPA-BB2-28F | monomer | 99.18 | 1×28I; | |||
uPA-31F | monomer | 99.18 | 1×32I; | |||
Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) … | monomer | 98.74 | 1×SO4; 2×BEN; 1×PG4; 1×PEG; | |||
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK9… | monomer | 99.18 | 2×SO4; 2×ACT; 2×GOL; 1×29O; | |||
Crystal structure of uPA in complex with upain-2-4-W3A | monomer | 99.18 | ||||
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6… | monomer | 99.18 | 2×SO4; 1×ACT; | |||
uPA-HMA | monomer | 99.18 | 1×9X9; 1×SO4; | |||
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6… | monomer | 99.18 | 2×SO4; 2×ACT; | |||
Crystal structure of uPA in complex with upain-2-4 | monomer | 99.18 | ||||
Crystal structure of bicyclic peptide UK729 bound as an acyl-enzyme intermediate to urokinase-type … | monomer | 99.18 | 1×SO4; 2×ACT; 1×ZBR; 1×GOL; | |||
Substituted 2-Naphthamidine Inhibitors of Urokinase | monomer | 99.18 | 3×SO4; 1×UI2; | |||
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK8… | monomer | 99.18 | 2×SO4; 1×GOL; 1×29N; | |||
Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) … | monomer | 98.78 | 1×SO4; 1×PG4; 1×PL0; | |||
Crystal structure of inactive uPA in complex with nafamostat | monomer | 98.78 | 1×7RF; | |||
uPA-NU-09F | monomer | 99.18 | 1×09I; | |||
Substituted 2-Naphthamidine Inhibitors of Urokinase | monomer | 99.59 | 1×UI3; | |||
The crystal structure of uPA in complex with HMA-55F | monomer | 99.18 | 1×H55; | |||
uPA-BB2-27F | monomer | 99.18 | 1×27I; | |||
Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activato… | monomer | 99.18 | 1×ZBR; | |||
uPA-BB2-94F | monomer | 99.18 | 1×94I; | |||
Substituted 2-Naphthamidine Inhibitors of Urokinase | monomer | 99.18 | 3×SO4; 1×UI1; | |||
Crystal structure of uPA in complex with cleaved camostat | monomer | 99.18 | 1×GBS; 2×PGE; | |||
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6… | monomer | 99.18 | 3×SO4; 1×ACT; 1×GOL; | |||
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6… | monomer | 99.18 | 2×SO4; 1×GOL; 1×ACT; 1×CL; | |||
Crystal structure of uPA in complex with nafamostat | monomer | 99.18 | 1×GBS; 2×PGE; | |||
Substituted 2-Naphthamadine inhibitors of Urokinase | monomer | 99.59 | 1×745; | |||
UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-AMILORIDE COMPLEX | monomer | 99.59 | 2×SO4; 1×AMR; | |||
Crystal structure of uPA-S195A in complex with S2444 | monomer | 98.78 | 1×7YR; | |||
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6… | monomer | 99.18 | 2×SO4; 1×ACT; | |||
Crystal structure of uPA_H99Y in complex with 31F | monomer | 98.78 | 1×32I; | |||
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6… | monomer | 99.18 | 2×SO4; | |||
Substituted 2-Naphthamidine inhibitors of urokinase | monomer | 99.59 | 1×497; | |||
Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic … | monomer | 99.16 | 1×4AZ; 1×SO4; | |||
Crystal structure of uPA in complex with 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-… | monomer | 99.18 | 1×9XC; | |||
Crystal structure of uPA_H99Y in complex with 50F | monomer | 98.78 | 1×50I; | |||
Substituted 2-Naphthamidine Inhibitors of Urokinase | monomer | 99.59 | 1×303; | |||
Substituted 2-Naphthamidine Inhibitors of Urokinase | monomer | 99.59 | 1×426; | |||
uPA-BB2-30F | monomer | 99.18 | 1×30I; | |||
Crystal structure of human microurokinase in complex with 2-amino-5-hydroxy-benzimidazole | monomer | 99.18 | 1×SO4; 1×172; | |||
Substituted 2-Naphthamidine Inhibitors of Urokinase | monomer | 99.59 | 1×155; | |||
SOLUTION STRUCTURE OF THE AMINO TERMINAL FRAGMENT OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR | monomer | 99.23 | 1×FUC; | |||
Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (ATF) | monomer | 99.19 | ||||
SEQUENTIAL 1H NMR ASSIGNMENTS AND SECONDARY STRUCTURE OF THE KRINGLE DOMAIN FROM UROKINASE | monomer | 98.82 | ||||
4 SWISS-MODEL models
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
2vnt.3.A | monomer | 0.83 | 1×QGG; | 99.64 | ||
3laq.1.A | monomer | 0.67 | 71.43 | |||
5edm.1.A | monomer | 0.60 | 29.48 | |||
1urk.1.A | monomer | 0.54 | 99.21 | |||
5 SWISS-MODEL models built on isoform sequence
Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|---|
Isoform 2 | 2vnt.3.A | monomer | 0.83 | 1×QGG; | 99.64 | ||
Isoform 2 | 3bt2.1.A | monomer | 0.68 | 97.60 | |||
Isoform 2 | 1urk.1.A | monomer | 0.59 | 98.40 | |||
Isoform 2 | 4nzq.1.A | monomer | 0.57 | 28.35 | |||
Isoform 2 | 5edk.1.A | monomer | 0.54 | 28.20 | |||